Antibody specifically binding to CLL1, preparation method therefor, and use thereof
By developing nano-antibody that specifically binds CLL1, the killing activity and tumor-inhibiting effect of CAR-T cells against AML was improved, and the problem of poor efficacy of CAR-T cell therapy on AML in the prior art was solved, achieving high specificity anti-tumor effects with low immunogenicity.
Patent Information
- Application Number
- PCT/CN2024/092299
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
The existing CAR-T cell therapy is poor in acute myeloid leukemia (AML), lacks high affinity and high specificity antibodies, and has high immunogenicity, which affects the therapeutic effect.
A nanoantibody specifically binds CLL1, with the complementary determination region of the VHH chain CDR region having a specific amino acid sequence, which is used to prepare high affinity and high biological activity CAR-T cells, which binds to the advantages of camel-derived antibodies to improve the Target cell killing activity and tumor inhibition effect against AML were used.
High specific killing and long-lasting anti-tumor efficacy against AML target cells is achieved, reducing immunogenicity and improving the effectiveness of treatment.
Smart Images

Figure PCTCN2024092299-FTAPPB-I100001 
Figure PCTCN2024092299-FTAPPB-I100002 
Figure PCTCN2024092299-FTAPPB-I100003
Abstract
Description
Antibodies specifically binding to CLL1 and their preparation and use Technical Field
[0001] The present invention relates to the field of engineered immunotherapy, and in particular to an antibody specifically binding to CLL1, and a preparation method and application thereof. Background Art
[0002] Acute myeloid leukemia (AML) is a disease characterized by heterogeneity in both treatment response and survival. Its primary characteristic is the arrest of differentiation of primitive progenitor cells and immature myeloid cells in the bone marrow and peripheral blood, leading to the abnormal proliferation and accumulation of primitive myeloid cells at various stages of differentiation and a dramatic decrease in normally functioning red blood cells, platelets, and white blood cells. AML commonly occurs in all age groups and is particularly common in the elderly (over 60 years of age), making it the most prevalent form of acute leukemia in adults. AML is a de novo, refractory, relapsing, and often lethal disease, making it a fatal disease. Common treatments include chemotherapy and hematopoietic stem cell transplantation.
[0003] Chimeric Antigen Receptor T cells (CAR T) are a new immunotherapy method that targets specific antigens on the surface of tumor cells. Currently, they are used in the development of cell therapy for tumors.
[0004] The advantages of camel-derived antibodies (or single-domain antibodies) include their stability, good water solubility, low immunogenicity, higher affinity, smaller molecular weight, and improved tissue penetration compared to traditional antibodies. Single-domain antibodies can be used as diagnostic tools and for the delivery of CAR-T and targeted drugs.
[0005] Therefore, there is an urgent need in this field to develop a new CAR-T with higher affinity, stronger specificity and / or lower immunogenicity for the treatment of acute myeloid leukemia.
[0006] Summary of the Invention
[0007] The purpose of the present invention is to provide an antibody with high affinity and high biological activity and capable of specifically recognizing CLL1 antigen and its application.
[0008] In a first aspect of the present invention, there is provided a Nanobody that specifically binds to CLL1, wherein the complementarity determining region (CDR) region of the VHH chain in the Nanobody has the following CDR1, CDR2 and CDR3:
[0009] (a) CDR1: the sequence of which is shown in SEQ ID No: 14, 11 or 20;
[0010] (b) CDR2: the sequence of which is shown in SEQ ID No: 12, 15, 17, or 19;
[0011] (c) CDR3: Its sequence is shown in SEQ ID No: 13, 16, 18, 21 or 22.
[0012] In another preferred embodiment, the complementarity determining region (CDR) region of the VHH chain in the Nanobody is selected from the following group:
[0013] (Y1) CDR1 set forth in SEQ ID NO: 14, CDR2 set forth in SEQ ID NO: 19, and CDR3 set forth in SEQ ID NO: 16;
[0014] (Y2) CDR1 set forth in SEQ ID NO: 14, CDR2 set forth in SEQ ID NO: 12, and CDR3 set forth in SEQ ID NO: 22;
[0015] (Y3) CDR1 set forth in SEQ ID NO: 14, CDR2 set forth in SEQ ID NO: 15, and CDR3 set forth in SEQ ID NO: 16;
[0016] (Y4) CDR1 set forth in SEQ ID NO: 14, CDR2 set forth in SEQ ID NO: 17, and CDR3 set forth in SEQ ID NO: 18;
[0017] (Y5) CDR1 set forth in SEQ ID NO: 14, CDR2 set forth in SEQ ID NO: 19, and CDR3 set forth in SEQ ID NO: 16;
[0018] (Y6) CDR1 set forth in SEQ ID NO: 11, CDR2 set forth in SEQ ID NO: 12, and CDR3 set forth in SEQ ID NO: 13;
[0019] (Y7) CDR1 shown in SEQ ID NO: 20, CDR2 shown in SEQ ID NO: 12, and CDR3 shown in SEQ ID NO: 21.
[0020] In another preferred embodiment, the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
[0021] In another preferred embodiment, the nanobody that specifically binds to CLL1 includes humanized antibodies, camel-derived antibodies, and chimeric antibodies.
[0022] In another preferred example, the amino acid sequence of the Nanobody that specifically binds to CLL1 is as shown in any one of SEQ ID NOs: 1 to 10.
[0023] In another preferred example, the amino acid sequence of the VHH chain of the Nanobody is selected from the following group: SEQ ID NO: 1 to 10, or a combination thereof.
[0024] In another preferred example, the CDR region of the Nanobody VHH chain comprises an amino acid sequence having a sequence similarity of at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 99% to any one of SEQ ID NOs: 1 to 10.
[0025] In another preferred example, the amino acid sequence of the Nanobody VHH chain CDR region comprises one or more amino acid substitutions compared to any one of SEQ ID NOs: 1 to 10, preferably conservative amino acid substitutions.
[0026] In another preferred embodiment, any one of the above amino acid sequences further includes a derivative sequence that is optionally added, deleted, modified and / or substituted with at least one (such as 1-3, preferably 1-2, more preferably 1) amino acid and can retain the ability to specifically bind to CLL1.
[0027] In another preferred embodiment, the CLL1 is CLL1 of a human or non-human mammal.
[0028] In another preferred embodiment, the CLL1 is CLL1 of human, mouse, rat, or non-human primate (such as monkey).
[0029] In the second aspect of the present invention, a multivalent antibody or an antibody against multiple epitopes that specifically binds to CLL1 is provided, wherein the multivalent antibody or the antibody against multiple epitopes comprises at least one antibody element against a CLL1 epitope, and the antibody element is the anti-CLL1 nanobody described in the first aspect of the present invention.
[0030] In another preferred example, the anti-CLL1 multivalent antibody or antibody targeting multiple epitopes includes one or more anti-CLL1 nanobodies.
[0031] In another preferred embodiment, the anti-CLL1 antibody includes monomers, divalents (bivalent antibodies), tetravalents (tetravalent antibodies), and / or multivalents (multivalent antibodies).
[0032] In another preferred embodiment, the anti-CLL1 antibody comprises one or more VHH chains having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 10.
[0033] In another preferred embodiment, the anti-CLL1 antibody comprises two VHH chains having the amino acid sequences shown in SEQ ID NOs: 1 to 10.
[0034] In another preferred embodiment, the antibody is selected from: animal-derived antibodies, chimeric antibodies, humanized antibodies, or a combination thereof.
[0035] In a third aspect of the present invention, a recombinant protein is provided, wherein the recombinant protein has:
[0036] (i) the nanobody that specifically binds to CLL1 according to the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes that specifically binds to CLL1 according to the second aspect of the invention; and
[0037] (ii) optionally a tag sequence to facilitate expression and / or purification.
[0038] In another preferred embodiment, the antibody is a multivalent antibody.
[0039] In another preferred embodiment, the tag sequence includes an Fc tag, an HA tag, a Flag tag and a 6His tag.
[0040] In another preferred embodiment, the Fc tag comprises mIgG2aFc.
[0041] In another preferred embodiment, the recombinant protein specifically binds to the CLL1 protein.
[0042] In a fourth aspect of the present invention, a chimeric antigen receptor (CAR) fusion protein is provided, characterized in that the chimeric antigen receptor (CAR) fusion protein comprises from the N-terminus to the C-terminus:
[0043] (i) an antigen-binding domain that specifically binds to CLL1, wherein the antigen-binding domain comprises the Nanobody according to the first aspect of the invention;
[0044] (ii) transmembrane domain;
[0045] (iii) at least one costimulatory domain; and
[0046] (iv) Activation domain.
[0047] In another preferred embodiment, the antigen binding domain is monovalent or multivalent.
[0048] In another preferred embodiment, the antigen binding domain is derived from the Nanobody described in the first aspect of the present invention or the recombinant protein described in the third aspect of the present invention.
[0049] In another preferred embodiment, the CAR has the structure shown in Formula Ia: L-VHH-FH-TM-C-CD3ζ (Ia)
[0050] Where,
[0051] Each "-" is independently a connecting peptide or a peptide bond;
[0052] L is the signal peptide sequence;
[0053] VHH is the antigen-binding domain that specifically binds to CLL1;
[0054] F is none or Flag tag sequence (Flag tag);
[0055] H is the hinge region;
[0056] TM is the transmembrane domain;
[0057] C is the costimulatory signaling domain;
[0058] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type, or mutants / modified forms thereof).
[0059] In another preferred embodiment, L is a signal peptide of a protein selected from the group consisting of CD28, 4-1BB, GM-CSF, CD3, CD8a or a combination thereof.
[0060] In another preferred embodiment, the L is a signal peptide derived from CD8.
[0061] In another preferred embodiment, the L comprises the amino acid sequence shown in SEQ ID NO: 27.
[0062] In another preferred embodiment, the amino acid sequence of the VHH is shown in any one of SEQ ID NOs: 1 to 10.
[0063] In another preferred embodiment, the H comprises the hinge region of CD28.
[0064] In another preferred embodiment, the TM includes a transmembrane region derived from CD28.
[0065] In another preferred embodiment, the amino acid sequences of H and TM comprise the sequence shown in SEQ ID No: 29.
[0066] In another preferred embodiment, the C is a transmembrane region of a protein selected from the group consisting of CD28, 4-1BB, CD8a or a combination thereof.
[0067] In another preferred embodiment, the C comprises a co-stimulatory signal molecule derived from 4-1BB.
[0068] In another preferred embodiment, the C comprises the amino acid sequence shown in SEQ ID No: 30.
[0069] In another preferred embodiment, the CD3ζ comprises the amino acid sequence shown in SEQ ID No: 31
[0070] In another preferred embodiment, the CAR fusion protein has an amino acid sequence shown in any one of SEQ ID NOs: 32-41.
[0071] In a fifth aspect of the present invention, an antibody-drug conjugate is provided, wherein the antibody-drug conjugate comprises:
[0072] (a) the Nanobody of the first aspect of the invention, the multivalent antibody or antibody against multiple epitopes of the second aspect of the invention, or the recombinant protein of the third aspect of the invention; and
[0073] (b) a conjugated moiety conjugated to the antibody portion, wherein the conjugated moiety is selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.
[0074] In another preferred embodiment, the antibody portion and the coupling portion are coupled via a chemical bond or a linker.
[0075] In the sixth aspect of the present invention, a polynucleotide is provided, which encodes a protein selected from the following group: the nanobody described in the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the invention, the recombinant protein described in the third aspect of the invention, or the CAR fusion protein described in the fourth aspect of the invention.
[0076] In the seventh aspect of the present invention, an expression vector is provided, wherein the expression vector contains the polynucleotide described in the sixth aspect of the present invention.
[0077] In another preferred embodiment, the expression vector is selected from the following group: DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or a combination thereof.
[0078] In another preferred embodiment, the expression vector is a lentiviral vector.
[0079] In the eighth aspect of the present invention, a host cell is provided, which contains the expression vector described in the seventh aspect of the present invention, or the polynucleotide described in the sixth aspect of the present invention is integrated into its genome, or expresses the nanoantibody described in the first aspect of the present invention, the multivalent antibody or antibody against multiple epitopes described in the second aspect of the present invention, the recombinant protein described in the third aspect of the present invention, or the CAR fusion protein described in the fourth aspect of the present invention.
[0080] In another preferred embodiment, the cell is an isolated cell, and / or the cell is a genetically engineered cell.
[0081] In another preferred embodiment, the cells are mammalian cells.
[0082] In another preferred embodiment, the cells are T cells.
[0083] In another preferred embodiment, the host cell is an engineered immune cell.
[0084] In another preferred embodiment, the engineered immune cells are selected from the following group:
[0085] (i) Chimeric antigen receptor αβ T cells (CAR-T cells);
[0086] (ii) chimeric antigen receptor γδ T cells (CAR-T cells);
[0087] (iii) chimeric antigen receptor NKT cells (CAR-NKT cells);
[0088] (iv) chimeric antigen receptor NK cells (CAR-NK cells);
[0089] (v) Chimeric antigen receptor macrophages.
[0090] In the ninth aspect of the present invention, a method for preparing engineered immune cells is provided, comprising the following steps: transducing the nucleic acid molecule described in the sixth aspect of the present invention or the vector described in the seventh aspect of the present invention into T cells or NK cells, thereby obtaining the engineered immune cells, wherein the engineered immune cells express the CAR fusion protein described in the fourth aspect of the present invention.
[0091] In another preferred embodiment, the method further comprises the step of performing functional and effectiveness testing on the obtained engineered immune cells.
[0092] In the tenth aspect of the present invention, a preparation is provided, which contains the nanobody described in the first aspect of the invention, the multivalent antibody or the antibody against multiple epitopes described in the second aspect of the invention, the recombinant protein described in the third aspect of the invention, the CAR fusion protein described in the fourth aspect of the invention, or the vector described in the seventh aspect of the invention, or the host cell described in the eighth aspect of the invention, and a pharmaceutically acceptable carrier, diluent or excipient.
[0093] In another preferred embodiment, the host cell is an engineered immune cell.
[0094] In the eleventh aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0095] (i) the Nanobody of the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes of the second aspect of the invention, or the recombinant protein of the third aspect of the invention, or an immune cell expressing the CAR fusion protein of the fourth aspect of the invention; and
[0096] (ii) a pharmaceutically acceptable carrier.
[0097] In another preferred embodiment, the conjugated portion of the immunoconjugate is a drug, a toxin, and / or a therapeutic isotope.
[0098] In another preferred embodiment, the pharmaceutical composition further contains other drugs for treating immune system diseases or tumor diseases.
[0099] In another preferred embodiment, the pharmaceutical composition is used to prepare a drug for preventing and / or treating a disease or condition associated with CLL1.
[0100] In another preferred embodiment, the disease or condition associated with CLL1 is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), or a combination thereof.
[0101] In the twelfth aspect of the present invention, a kit is provided, which contains the nucleic acid molecule described in the sixth aspect of the present invention, the recombinant protein described in the third aspect of the present invention, or the vector described in the seventh aspect of the present invention.
[0102] In another preferred embodiment, the kit is used to prepare immune cells expressing the receptor CAR fusion protein described in the fourth aspect of the present invention.
[0103] In the thirteenth aspect of the present invention, there is provided the use of the nanoantibody described in the first aspect of the present invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the present invention, or the recombinant protein described in the third aspect of the present invention, or the immune cell expressing the CAR fusion protein described in the fourth aspect of the present invention, for the preparation of a medicament for preventing and / or treating cancers or tumors associated with CLL1.
[0104] In the fourteenth aspect of the present invention, a method for treating a disease is provided, comprising administering to a subject in need of treatment: the nanoantibody described in the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the invention, or the recombinant protein described in the third aspect of the invention, or immune cells expressing the CAR fusion protein described in the fourth aspect of the invention.
[0105] In another preferred embodiment, the disease is a tumor positive for CLL1 expression.
[0106] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one.
[0107] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0108] Figure 1 shows the expression of CLL1 on the surface of target cells.
[0109] Figure 2 shows the CAR positivity rate on the surface of CLL1 C-CAR-T cells.
[0110] Figure 3 shows the killing results of CLL1 C-CAR-T on wild-type Hela and CLL1 overexpressing Hela cells (RTCA method).
[0111] Figure 4 shows the killing results of CLL1 C-CAR-T on K562, KG1 and HL60 cells (luciferase method).
[0112] FIG5 shows the recognition of target cell surface antigens by CLL1 antibodies.
[0113] Figure 6 shows the CAR positivity rate on the surface of CLL1 F-CAR T cells.
[0114] Figure 7 shows a schematic diagram of the flow cytometric analysis process for multiple rounds of CAR-T cell killing in vitro.
[0115] Figure 8 shows the results of multiple rounds of killing of HL60 cells by CLL1 C-CAR T and CLL1 F-CAR T cells.
[0116] Figure 9 shows the results of multiple rounds of killing of KG1 cells by CLL1 C-CAR T and CLL1 F-CAR T cells.
[0117] FIG10 shows the CAR-positive rate after CAR-NK92 sorting.
[0118] FIG11 shows the results of CAR-NK92 killing of tumor cells (luciferase method).
[0119] FIG12 shows the multi-round killing results of CAR-NK92. DETAILED DESCRIPTION
[0120] After extensive and in-depth research, the inventors unexpectedly obtained a class of anti-CLL1 antibodies with excellent affinity and high anti-tumor activity for the first time. Specifically, after a large number of screenings, the inventors obtained for the first time multiple nanobodies that specifically bind to CLL1. Based on the nanobodies, the present invention further prepared recombinant antibodies and humanized antibodies, as well as chimeric antigen receptors targeting CLL1. Based on the alpaca heavy chain antibody that specifically binds to CLL1, the present invention provides CAR-T with higher affinity, stronger specificity for the target antigen, and lower immunogenicity compared to traditional antibodies. The CAR-T cells of the present invention have excellent target cell killing activity and in vivo tumor inhibition effect. The present invention was completed on this basis.
[0121] Specifically, the present invention utilizes human CLL1 antigen protein to immunize alpacas to obtain a high-quality immune nanobody gene library. CLL1 protein molecules are then coupled to an ELISA plate to display the correct spatial structure of the CLL1 protein. This antigen is then used to screen the immune nanobody gene library (alpaca heavy chain antibody phage display gene library) using phage display technology, thereby obtaining nanobody genes specific for the CLL1 protein. These genes are then transferred into Escherichia coli to obtain a nanobody strain that can be efficiently expressed in E. coli and has high specificity.
[0122] the term
[0123] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0124] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0125] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0126] Sequence identity is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0127] As used herein, the terms "heavy chain variable region" and "V H ” can be used interchangeably.
[0128] As used herein, the terms "variable region" and "complementarity determining region (CDR)" are used interchangeably.
[0129] In the present invention, the terms "antibody of the present invention," "single-domain antibody of the present invention," "protein of the present invention," or "polypeptide of the present invention" are used interchangeably to refer to antibodies that specifically bind to CLL1, such as proteins or polypeptides having a heavy chain variable region (such as the amino acid sequences shown in SEQ ID NOs: 1-10). These may or may not contain an initial methionine.
[0130] CLL1
[0131] C-type lectin-like 1 (CLL1), also known as C-type lectin domain family 12 member A (CLEC12A) and CD371, is a type II transmembrane protein. CLL1 is a member of the large family of C-type lectin-like receptors and glycoprotein receptors involved in immune regulation. CLL1 is expressed in hematopoietic cells, primarily in innate immune cells and myeloid progenitor cells, including monocytes, dendritic cells (DCs), and granulocytes.
[0132] CLL-1 is also expressed in acute myeloid leukemia (AML) blasts and leukemic stem cells (e.g., CD34 + / CD38 - CLL1 expression may also be found on the cell surface of other myeloid leukemias, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS).
[0133] Studies have shown that CLL1 is expressed in AML stem cells (CD34 + / CD38 - ) and a small number of hematopoietic progenitor cells (CD34 + / CD38 + or CD34 + / CD33 + ) but in normal hematopoietic stem cells (CD34 + / CD38 - or CD34 + / CD33 - ) is not expressed.
[0134] Therefore, single-domain antibodies targeting CLL1 and CAR-engineered immune cells (such as CAR-T cells) can be used to treat myeloid leukemias with high CLL1 expression. Representative examples include (but are not limited to): acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS).
[0135] Antibody
[0136] As used herein, the term "antibody" refers to immunoglobulins, which are tetrapeptide chains composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds.
[0137] As used herein, the terms "single-domain antibody (VHH)" and "nanobody" have the same meaning and refer to the cloning of the variable region of an antibody heavy chain to construct a single-domain antibody (VHH) consisting of only a single heavy chain variable region. This is the smallest antigen-binding fragment with complete function. Typically, an antibody naturally lacking the light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting of only a single heavy chain variable region.
[0138] Existing antibody numbering schemes include:
[0139] 1. The Kabat scheme (Kabat et al., 1991) is based on the location of regions of high sequence variation between sequences of the same domain type, with antibody heavy (VH) and light (Vλ and Vκ) variable domains numbered differently.
[0140] 2. The Chothia program (Al-Lazikani, 1997) is identical to Kabat's, but corrects the position of the insertion annotation around the first VH complementarity-determining region (CDR) to correspond to the structural loop. Similarly, the enhanced Chothia program (Abhinandan and Martin, 2008) further structurally corrects the insertion position.
[0141] 3. In contrast to these Kabat-like schemes, IMGT (Lefranc, 2003) and AHo (Honegger and Plückthun, 2001) both define unique schemes for variable domains of antibodies and T-cell receptors (TCRs) (Vα and Vβ). Therefore, equivalent residue positions can be easily compared between domain types. IMGT and AHo differ in the number of positions they annotate (128 and 149, respectively) and the locations where they consider indels to occur.
[0142] The amino acid composition and arrangement order of the constant region of immunoglobulins (Ig) heavy chains vary, resulting in different antigenic properties. Consequently, immunoglobulins can be divided into five classes, or isotypes, namely IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Igs within the same class are further divided into subclasses based on the amino acid composition of their hinge regions and the number and location of disulfide bonds in the heavy chains. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as either kappa or lambda chains, depending on the constant region. Each of the five Ig classes can have either kappa or lambda chains. The subunit structures and three-dimensional configurations of different immunoglobulin classes are well known in the art.
[0143] The antibody light chain of the present invention may further comprise a light chain constant region, wherein the light chain constant region comprises a human or murine κ, λ chain or a variant thereof.
[0144] In the present invention, the antibody heavy chain described in the present invention may further comprise a heavy chain constant region, wherein the heavy chain constant region comprises human or murine IgG1, IgG2, IgG3, IgG4 or variants thereof. The sequence of approximately 110 amino acids near the N-terminus of the antibody heavy and light chains varies greatly and is the variable region (Fv region); the remaining amino acid sequence near the C-terminus is relatively stable and is the constant region. The variable region includes three hypervariable regions (HVRs) and four framework regions (FRs) with relatively conserved sequences. The three hypervariable regions determine the specificity of the antibody and are also called complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, arranged in the order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The three CDR regions of the light chain are referred to as LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain are referred to as HCDR1, HCDR2, and HCDR3.
[0145] The term "murine antibody," as used herein, refers to anti-CLL1 monoclonal antibodies prepared according to the knowledge and skill in the art. These antibodies are prepared by injecting a test subject with a CLL1 antigen, followed by isolation of hybridomas expressing antibodies with the desired sequence or functional properties. In a preferred embodiment of the present invention, the murine CLL1 antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a murine kappa or lambda chain, or variants thereof, or a heavy chain constant region of a murine IgG1, IgG2, IgG3, or variants thereof.
[0146] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can reduce the immune response induced by the mouse antibody.
[0147] The term "humanized antibody", also known as CDR-grafted antibody, refers to an antibody produced by transplanting mouse CDR sequences into the human antibody variable region framework, that is, different types of human germline antibody framework sequences. Humanized antibodies can overcome the heterologous reactions induced by chimeric antibodies due to the large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases or published references including germline antibody gene sequences. In order to avoid a decrease in immunogenicity and the resulting decrease in activity, the human antibody variable region framework sequence can be subjected to minimal reverse mutation or back mutation to maintain activity.
[0148] The term "antigen-binding fragment of an antibody" (or simply "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., CLL1). It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment of an antibody" include
[0149] (i) Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains;
[0150] (ii) F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region;
[0151] (iii) an Fd fragment consisting of the VH and CH1 domains;
[0152] (iv) An Fv fragment consisting of the VH and VL domains of a single arm of an antibody.
[0153] Fv antibodies contain the variable regions of the antibody heavy chain and light chain, but no constant region, and are the smallest antibody fragments with all antigen-binding sites. Generally, Fv antibodies also include a polypeptide linker between the VH and VL domains and are able to form the structure required for antigen binding.
[0154] The term "CDR" refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contributes to antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication, No. 91-3242).
[0155] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a specific site on a CLL1 molecule). An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous or non-contiguous amino acids in a unique spatial conformation.
[0156] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. -7 M, for example, less than approximately 10 -8 M, 10 -9 M or 10 10 Binds with an affinity (KD) of M or less.
[0157] The term "competitive binding" refers to an antibody that recognizes the same epitope (also referred to as an antigenic determinant) or a portion of the same epitope on the extracellular region of CLL1 as the monoclonal antibody of the present invention and binds to the antigen. An antibody that binds to the same epitope as the monoclonal antibody of the present invention refers to an antibody that recognizes and binds to the amino acid sequence of CLL1 recognized by the monoclonal antibody of the present invention.
[0158] The term "KD" or "Kd" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. Typically, the antibodies of the invention exhibit dissociation equilibrium constants of less than about 10 -7 M, for example, less than about 10 -8 M, 10 -9 M or 10 -10 The cytochrome P4000 binds to CLL1 with a dissociation equilibrium constant (KD) of M or less.
[0159] As used herein, the term "antigenic determinant" refers to a discrete three-dimensional site on an antigen that is recognized by the antibodies or antigen-binding fragments of the present invention.
[0160] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0161] In the present invention, antibodies include murine, chimeric, humanized, or fully human antibodies prepared using techniques well known to those skilled in the art. Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, including human and non-human portions, can be prepared using recombinant DNA techniques well known in the art.
[0162] As used herein, the term "monoclonal antibody" refers to an antibody secreted by a clone derived from a single cell. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. The cell may be a eukaryotic, prokaryotic, or phage clone.
[0163] In the present invention, the antibodies can be monospecific, bispecific, trispecific, or more multispecific.
[0164] In the present invention, the antibodies of the present invention also include conservative variants thereof, which refer to polypeptides in which no more than 10, preferably no more than 8, more preferably no more than 5, and most preferably no more than 3 amino acids are replaced with amino acids having similar or similar properties, compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by making amino acid substitutions according to Table A below.
[0165] Table A
[0166] Anti-CLL1 humanized antibody
[0167] The present invention provides a humanized anti-CLL1 antibody. Specifically, the present invention provides a highly specific and high-affinity humanized antibody against CLL1, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH) amino acid sequence, and the light chain comprises a light chain variable region (VL) amino acid sequence.
[0168] There are two common options for human framework regions in antibody humanization: known mature antibodies or human germline sequences. The framework regions of known mature antibodies often contain somatic mutation sites, which may confer potential immunogenicity. Compared to mature antibodies, human germline sequence framework regions are theoretically less immunogenic and more structurally flexible, with increased plasticity and the ability to accommodate diverse CDR regions. Human antibody germline genes have a certain frequency of usage in the human body. Humanized antibodies using frequently used germline framework regions exhibit advantages such as low immunogenicity, high expression levels, and structural stability.
[0169] In a preferred embodiment of the present invention, multiple factors (including similarity and frequency of human use) were considered during humanization. After extensive experimental screening, optimal framework sequences were selected for humanization. The humanized antibody germline framework region was selected for CDR grafting. This resulted in a more stable humanized antibody structure, higher expression levels, lower immunogenicity, and improved drugability.
[0170] In another preferred embodiment, the heavy chain constant region and / or light chain constant region may be a humanized heavy chain constant region or light chain constant region. More preferably, the humanized heavy chain constant region or light chain constant region is a heavy chain constant region of human IgG1, IgG2, etc., or a human kappa or lambda light chain constant region.
[0171] In another preferred embodiment, the sequence formed by adding, deleting, modifying and / or replacing at least one amino acid sequence is preferably an amino acid sequence with a homology of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
[0172] The antibody of the present invention may be a double-chain or single-chain antibody, and may preferably be a fully humanized antibody.
[0173] The antibody derivatives of the present invention can be single-chain antibodies and / or antibody fragments, such as Fab, Fab', (Fab')2, or other antibody derivatives known in the art, as well as any one or more of IgA, IgD, IgE, IgG, IgM antibodies or other subtypes of antibodies.
[0174] The antibodies of the present invention may be humanized antibodies, CDR-grafted and / or modified antibodies targeting CLL1.
[0175] In the above content of the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably not more than 40% of the total number of amino acids in the initial amino acid sequence, more preferably not more than 35%, more preferably 1-33%, more preferably 5-30%, more preferably 10-25%, more preferably 15-20%.
[0176] Antibody preparation
[0177] Any method suitable for producing monoclonal antibodies can be used to produce the CLL1 antibodies of the present invention. For example, animals can be immunized with a linked or naturally occurring CLL1 protein or fragments thereof. Suitable immunization methods can be used, including adjuvants, immunostimulants, and repeated booster immunizations, and one or more routes can be used.
[0178] Any suitable form of CLL1 can be used as an immunogen (antigen) to produce non-human antibodies specific for CLL1 and screen the biological activity of the antibodies. The immunogen can be used alone or in combination with one or more immunogenicity enhancers known in the art. The immunogen can be purified from a natural source or produced in genetically modified cells. The DNA encoding the immunogen can be genomic or non-genomic (e.g., cDNA) in origin. The DNA encoding the immunogen can be expressed using a suitable genetic vector, including but not limited to adenoviral vectors, baculoviral vectors, plasmids, and non-viral vectors.
[0179] Humanized antibodies can be selected from any class of immunoglobulins, including IgM, IgD, IgG, IgA, and IgE. Similarly, any class of light chain can be used in the compounds and methods herein. Specifically, kappa, lambda chains, or variants thereof can be used in the compounds and methods of the present invention.
[0180] The sequence of the DNA molecule of the antibody of the present invention or its fragment can be obtained by conventional techniques, such as PCR amplification or genomic library screening. In addition, the coding sequences of the light chain and heavy chain can be fused together to form a single-chain antibody.
[0181] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.
[0182] In addition, artificial synthesis methods can also be used to synthesize relevant sequences, especially when the fragment length is relatively short. Generally, by first synthesizing multiple small fragments and then connecting them, very long fragments of sequence can be obtained. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art.
[0183] The term "nucleic acid molecule" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0184] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated.
[0185] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0186] The term "host cell" refers to a cell into which an expression vector has been introduced. The host cell can be a prokaryotic cell, such as a bacterial cell, a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a plant or animal cell (e.g., a mammalian cell).
[0187] The steps of transforming host cells with recombinant DNA described in the present invention can be carried out using techniques well known in the art. The transformants obtained can be cultured using conventional methods, and the transformants express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, conventional culture medium is used under appropriate conditions.
[0188] Typically, the transformed host cells are cultured under conditions suitable for expression of the antibodies of the present invention. The antibodies of the present invention are then purified using conventional immunoglobulin purification procedures, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, or affinity chromatography, among other conventional separation and purification methods well known to those skilled in the art.
[0189] The resulting monoclonal antibodies can be characterized by conventional means. For example, the binding specificity of the monoclonal antibodies can be determined by immunoprecipitation or in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).
[0190] Antibody preparations
[0191] Antibodies exhibit varying stability in different formulation buffers, manifesting as changes in charge heterogeneity, degradation of antibody molecules, and aggregation. These changes in quality properties are related to the physical and chemical properties of the antibodies themselves. Therefore, during the antibody drug development process, it is necessary to screen formulation buffers suitable for each antibody based on its physical and chemical properties. Currently, commonly used antibody formulation buffer systems include phosphate buffer, citrate buffer, and histidine buffer. Depending on the properties of the antibody, varying concentrations of salt ions or excipients such as sorbitol, trehalose, and sucrose, as well as appropriate amounts of surfactants such as Tween, are added to maintain antibody stability.
[0192] Pharmaceutical composition
[0193] The present invention also provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein or its ADC or corresponding CAR-T cell, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary with the properties of the formulated substance and the condition to be treated. The prepared pharmaceutical composition can be administered by conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or local administration.
[0194] The antibodies of the present invention can also be expressed in cells by nucleotide sequences for cell therapy, for example, the antibodies are used in chimeric antigen receptor T cell immunotherapy (CAR-T) and the like.
[0195] The pharmaceutical composition of the present invention can be used to directly bind to CLL1 protein molecules, and thus can be used to prevent and treat CLL1-related diseases. In addition, other therapeutic agents can also be used simultaneously.
[0196] The pharmaceutical composition of the present invention contains a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-mentioned monoclonal antibody of the present invention (or its conjugate) and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, using physiological saline or an aqueous solution containing glucose and other adjuvants by conventional methods. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 μg / kg body weight to about 5 mg / kg body weight per day. In addition, the polypeptide of the present invention can also be used in conjunction with other therapeutic agents.
[0197] When using a pharmaceutical composition, a safe and effective amount of the pharmaceutical composition is administered to a mammal, wherein the safe and effective amount is generally at least about 10 μg / kg body weight, and in most cases does not exceed about 50 mg / kg body weight. Preferably, the dosage is about 10 μg / kg body weight to about 20 mg / kg body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the skill of a skilled physician.
[0198] Detection Uses and Kits
[0199] The antibodies of the present invention can be used in detection applications, for example, for detecting a sample to provide diagnostic information.
[0200] In the present invention, the samples used include cells, tissue samples and biopsy specimens. The term "biopsy" as used in the present invention should include all types of biopsies known to those skilled in the art. Therefore, the biopsy used in the present invention can include, for example, tissue samples prepared by endoscopic methods or puncture or needle biopsy of an organ.
[0201] Samples used in the present invention include fixed or preserved cell or tissue samples.
[0202] The present invention also provides a kit containing the antibody (or fragment thereof) of the present invention. In a preferred embodiment of the present invention, the kit further comprises a container, instructions for use, a buffer, etc. In a preferred embodiment, the antibody of the present invention can be fixed to a detection plate.
[0203] The main advantages of the present invention include:
[0204] (a) The single-domain antibody (VHH domain) against CLL1 of the present invention has high specificity and affinity.
[0205] (b) The CLL1 CAR T cells of the present invention exhibit highly specific in vitro cytotoxicity against CLL1-positive target cells.
[0206] (c) The CLL1 CAR T cells of the present invention can effectively inhibit the growth of CLL1-positive tumors in vivo and show long-lasting anti-tumor efficacy.
[0207] (d) The antibody of the present invention can be used to specifically detect CLL1 protein.
[0208] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0209] Example 1. Alpaca antibody screening
[0210] Single-domain antibodies (i.e., alpaca antibodies or VHH antibodies) are obtained by screening from a phage antibody library. The alpaca antibody library establishment process is briefly described as follows: the antigen and adjuvant are mixed and emulsified, and the alpaca is immunized with three subcutaneous injections. After the three immunizations, blood samples are collected to isolate PBMCs. Total RNA from the PBMCs is extracted and reverse-transcribed into cDNA. VHHs are amplified by nested PCR, and the VHH fragments are then inserted into phagemids. The phages are amplified and harvested to obtain the antibody library.
[0211] CLL1 antibody screening was performed by protein panning as follows: overnight coating with CLL1 antigen, adding the antibody library after blocking and incubating for 1 hour the next day, washing 8-10 times after the incubation, eluting the bound phage and amplifying it, isolating and purifying the amplified phage for the next round of screening.
[0212] After screening for enrichment, the enriched phage is used to infect the host bacteria. Resistance plates are then plated and ≥96 single clones / pool are randomly selected for culture. The overnight culture supernatant is collected and positive clones are identified by phage ELISA. Based on the OD value (Pro) of the phage ELISA-positive wells and the difference (Pro / PVA) from the control wells (PVA), multiple single clones are selected for sequencing. Sequences with sequencing anomalies are further eliminated and clones with identical sequences are merged.
[0213] result
[0214] Based on the affinity ranking of the positive monoclonal antibodies and the frequency of occurrence of the enriched antibodies, 10 single-domain antibodies that bind to CLL1 were finally obtained. The amino acid sequences and CDR corresponding SEQ ID Nos: are described in Tables 1, 2 and 3 below.
[0215] Table 1 Amino acid sequences of CLL1 single domain antibodies
[0216] Table 2 CDR amino acid sequences of CLL1 single domain antibody
[0217] Table 3 Sequence numbering (SEQ ID No) of CLL1 single domain antibody
[0218] Note: These antibodies have identical CDRs. If identical sequences are numbered identically, the numbers after removing the duplicates are as follows: Among them, the three CDRs of antibodies C6, C7, and C8 are identical; the three CDRs of C9 and C10 are identical.
[0219] Example 2. Cell culture and construction
[0220] CLL1-expressing cell lines HL60-LucG and KG1-LucG, as well as CLL1-non-expressing K562-LucG, were cultured in RPMI 1640 medium. 293T cells and wild-type and CLL1-expressing HeLa cells (HeLa-WT and HeLa-CLL1) were cultured in DMEM medium. All media were supplemented with 10% (v / v) fetal bovine serum, 100 U / ml penicillin and streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate. Cells were cultured at 37°C, 5% CO2, and saturated humidity.
[0221] Among them, Hela cells expressing CLL1 are stable cell lines obtained by transferring CLL1 antigen through a lentiviral vector, and can specifically express CLL1 protein molecules. HL60-LucG cells, KG1-LucG cells, and K562-LucG cells are stable cell lines obtained by screening after infection with a lentivirus expressing firefly luciferase-GFP (T2A connection).
[0222] The expression of target cell surface antigens is shown in Figure 1. Hela-CLL1 is a cell that overexpresses CLL1, Hela-WT and K562 are CLL1-negative cells, and KG1 and HL60 are CLL1-positive cells. The abundance of CLL1 protein on the surface of HL60 cells is higher than that on the surface of KG1 cells.
[0223] Example 3. Preparation of CLL1 C-CAR T cells
[0224] The CLL1 CAR gene consists of a CD8 signal peptide, a VHH or scFv that recognizes CLL1, a CD8 hinge and transmembrane region, a 4-1BB signal region, and a CD3z signal region.
[0225] The CLL1 CAR gene is placed under the EF1α (EF-1α) promoter to create a CLL1 CAR expression vector. CLL1 CAR expression vectors are numbered C1, C2, C3, …, C9, and C10 based on their VHH sequences. CLL1 CAR expression vectors constructed using other scFvs that recognize CLL1 are named using their scFv clone numbers, such as M26.
[0226] The amino acid sequence of the CLL1 C-CAR of the present invention is shown in SEQ ID No: 32-41, and the amino acid sequence of the scFV-based M26CAR is shown in SEQ ID No: 42.
[0227] 2.5×10 6 293T cells were seeded in 150 cm2 culture dishes in DMEM medium containing 10% FBS and cultured overnight at 37°C, 5% CO2 and saturated humidity before transfection.
[0228] The next day, the helper plasmid and CLL1 CAR expression vector were added to a centrifuge tube containing 13.8 mL of Opti MEM medium, and 80 μg of PEI was added to the tube to obtain a mixture. The mixture was allowed to stand at room temperature for 20 minutes, and then 12 mL of Opti MEM medium was supplemented to obtain the transfection medium. For transfection, after removing the culture medium, the 293T cells were incubated with the transfection medium for 4-6 hours, and then the transfection medium was replaced with 20 mL of DMEM medium containing 2% FBS. After 72 hours, the culture medium was collected and centrifuged at 3000 g and 4 ° C for 15 minutes. The supernatant was further centrifuged at 27000 g and 4 ° C for 2 hours. The precipitate was collected and resuspended with 400 μL of pre-chilled X-VIVO medium to obtain the CLL1 CAR lentiviral suspension and kept at 4 ° C overnight. The next day, the viral suspension was aliquoted for further use.
[0229] T cells were cultured in X-VIVO medium supplemented with 1% human albumin, 4% serum replacement, and 300 IU / mL human interleukin-2 (hIL-2). Pan T cells were activated by incubation with CD3 / CD28 Dynabeads at a 1:1 ratio (CD3 / CD28 Dynabeads:T cells) and 300 IU / mL IL-2. After 2 days, the Dynabeads were removed using a magnetic column and then incubated at 37°C at 1 × 10 6 T cells were transfected with CLL1 CAR virus at a cell density of 10 cells / mL. The transfected cells were cultured and expanded. Samples were taken to detect cell number on the third day after infection and before freezing. CLL1 antigen was used to detect the proportion of CLL1 CAR-positive cells, that is, the CAR positivity rate of T cells. Half of the culture medium was replaced every 2-3 days. CLL1 C-CAR T cells were harvested on the eighth day after infection.
[0230] Figure 2 shows the CAR positivity rate of CLL1-C-CAR-T cells detected using CLL1 antigen. The CAR positivity rate of each group was above 50%.
[0231] Example 4. CLL1 C-CAR T cell killing in vitro
[0232] In this example, an in vitro killing experiment was performed on the CLL1 C-CAR T cells obtained above.
[0233] 4.1 RTCA test
[0234] The RTCA method was used to test the killing ability of CAR-T cells against Hela cell lines whose target cells overexpressed CLL1.
[0235] The results are shown in Figure 3. Under both effector-target ratios, the NT control group showed no killing effect on Hela-CLL1 cells, while CLL1 C-CAR T cells were able to exert specific killing activity against CLL1. Under both effector-target ratios, the killing effects of CLL1 C-CAR T cells in each group against Hela cells overexpressing CLL1 were similar.
[0236] 4.2 Luciferase assay
[0237] Luciferase-labeled tumor target cells are used to test their killing ability. By transferring the luciferase gene into target cells and screening clones, stable transfected cell lines HL60-LucG and KG1-LucG were obtained. During the experiment, luciferin substrate is added, and the luciferase reacts with luciferin to produce fluorescence. The intensity of the fluorescence can be used to determine the activity of the luciferase, and the cell survival rate can be measured to determine the killing effect of each CAR-T cell.
[0238] The results are shown in Figure 4. At the same E:T ratio, NT cells had no killing function, CLL1 C-CAR T cells had a dose-dependent killing effect on HL60-LucG cells and KG1-LucG cells, and CLL1 C-CAR T cells had no killing ability on K562-LucG cells.
[0239] In summary, after co-culture of CAR-T cells with target cells (CLL1-overexpressing Hela cells, CLL1-positive tumor cells, HL60 and KG1 cells), the target cells can be lysed by CAR-T cells targeting CLL1; and there is no non-specific killing of non-target cells (wild-type Hela cells, and CLL1-negative K562 cells).
[0240] Example 5. Recognition of target cell surface antigens by CLL1 antibodies
[0241] The CLL1 antibodies used were synthesized and purified (with the Fc fragment of mouse IgG 2a added to the C-terminus of VHH or scFv). These antibodies were serially diluted and used to label the CLL1 antigen on the surface of HL60 cells to analyze the recognition ability of these antibodies for the target cell surface antigen.
[0242] The analysis results are shown in Figure 5. Compared with the scFv antibody M26, the single-domain antibodies C1, C3, C5, C7, and C9 of the present invention can recognize CLL1 on the surface of HL60 cells with a higher positive rate, and under the same antibody dosage conditions, they have higher average fluorescence intensity than M26.
[0243] Example 6. Preparation of CLL1 F-CAR T cells
[0244] Peripheral blood was collected from healthy donors and PBMCs were isolated by density gradient centrifugation at 500–600 g for 20–30 minutes. Magnetic beads conjugated to CD28 and CD3 antibodies (CD3 / CD28 Dynabeads) were used to sort and enrich T cells. T cells bound to CD3 / CD28 Dynabeads were further incubated with 300 IU / mL IL-2 to activate the cells. Simultaneously, 0.1–10 × 10 6 Cells are transfected with the CLL1 CAR virus overnight at a density of 10 cells / mL. The cells are washed with saline buffer the next day and then directly frozen. FAST CAR T cells are obtained without further expansion. During this process, the cells become activated and are also referred to as CLL1 F-CAR T cells.
[0245] The CAR positive rate of CLL1 F-CAR T cells needs to be calibrated after recovery. After recovery, CLL1 F-CAR T cells were cultured at 37°C in the presence of 300 IU / mL IL2 at a rate of 1×10 6 The cells were cultured at a density of 1×10 cells / mL and 1×10 5 The CLL1 antigen was used to detect the proportion of CLL1 CAR-positive cells in each cell sample.
[0246] The results are shown in Figure 6. The expression of CLL1 CAR can be detected on the surface of the produced CLL1 F-CAR T, with a positive rate of about 30%.
[0247] Example 7. Multiple rounds of killing by CLL1 C-CAR T and CLL1 F-CAR T cells in vitro
[0248] On the first day, CLL1 F-CAR T cells were revived and incubated at 37°C at a concentration of 1 × 10 6 The cells were cultured at a density of 1×10 cells / mL and 300 IU / mL IL2. The CLL1 C-CAR T cells were revived on the next day and incubated at 37°C at a density of 1×10 6 The cells were cultured at a density of 10 cells / mL and 300 IU / mL IL2. On the third day, 1×10 5 The proportion of CLL1 CAR-positive cells in each cell sample was detected using CLL1 antigen.
[0249] According to the cell CAR positive rate shown in Figure 6, 2×10 5 CAR-positive CLL1 C-CAR T and CLL1F-CAR T were respectively combined with HL60-LucG (6×10 5 , E:T is 1:3) and KG1-LucG (4×10 5 The cells were co-cultured with E:T of 1:2 for multiple rounds of killing analysis.
[0250] On day 3 of each round, a portion of the co-cultured cells was removed for analysis by flow cytometry. The analysis process is shown in Figure 7, and the specific method is described as follows: 7AAD-negative live cell populations were circled from the main cell population, and then T cells (GFP-negative) and target cells (GFP-positive) were distinguished by GFP signal. The CAR positivity rate was analyzed using CLL1 antigen markers in the T cell population. Based on the results of flow cytometry analysis and cell counting, the same number of CLL1 CAR-T cells were removed and supplemented with tumor cells to a fixed effector-target ratio (E:T of 1:3 for HL60-LucG and 1:T of 1:2 for KG1-LucG) for the next round of killing experiments.
[0251] The results of multiple rounds of killing against HL60 target cells are shown in Figure 8 . Figure 8A shows the changes in CAR positivity during multiple rounds of killing against HL60 by CLL1 C-CAR T and CLL1 F-CAR T cells; Figure 8B shows the number of residual target cells (HL60) at the end of each round by CLL1 C-CAR T and CLL1F-CAR T cells; Figure 8C shows the total fold expansion of CAR T cells during multiple rounds of killing against HL60 by CLL1 C-CAR T and CLL1F-CAR T cells. Figure 8B shows that CLL1 F-CAR T cells have a stronger killing ability against HL60 cells than CLL1 C-CAR T cells; at the end of the fourth round, all CLL1 C-CAR T cells were unable to inhibit HL60 cells, and the CAR positivity rate decreased significantly (Figure 8A); at the end of the fourth round, CLL1F-CAR T cells had a stronger inhibitory effect on HL60 than M26, and C9 F-CAR T cells maintained a good CAR positivity rate (Figure 8A). As can be seen from Figure 8C, in multiple rounds of killing against HL60, the expansion of CLL1 F-CAR T was better than that of CLL1C-CAR T; among the CLL1 F-CAR T cells, the expansion fold of C9 was greater than that of M26.
[0252] The results of multiple rounds of killing against KG1 target cells are shown in Figure 9. Figure 9A shows the changes in CAR positivity during multiple rounds of killing against KG1 by CLL1 C-CAR T and CLL1 F-CAR T cells; Figure 9B shows the number of residual target cells (KG1) at the end of each round by CLL1 C-CAR T and CLL1F-CAR T cells; Figure 9C shows the total expansion fold of CAR T cells during multiple rounds of killing against KG1 by CLL1 C-CAR T and CLL1F-CAR T cells. At the end of the third round, all CLL1 C-CAR T cells were unable to inhibit KG1 cells well, but CLL1 F-CAR T cells were still able to inhibit KG1 cells well, and their CAR positivity rate was higher than that of CLL1 C-CAR T cells (Figure 9A). As can be seen from Figure 9C, in multiple rounds of killing against KG1, the expansion of CLL1 F-CAR T cells was better than that of CLL1 C-CAR T cells; within the CLL1 F-CAR T, the expansion fold of C9 was greater than that of M26.
[0253] Example 8. NK92 cells and culture methods
[0254] The complete culture medium for NK92 cells is AlphaMEM supplemented with 12.5% FBS, 12.5% Horse Serum, 1% Pen / Strep, 1% sodium pyruvate, 1% L-glutamine, and 100 U IL2. The complete culture medium for HL60, Molm13, KG-1, THP-1, and K562 cells is RPMI1640 supplemented with 10% FBS, 1% Pen / Strep, 1% sodium pyruvate, and 1% L-glutamine. Cells were cultured at 37°C, 5% CO2, and saturated humidity.
[0255] Example 9. CAR-NK92 lentiviral packaging and transfection
[0256] Resuscitation 293T inoculated one 150cm 2 The culture dish was placed in a CO2 incubator and cultured for 72 hours. After two passages, the culture dish was inoculated in a 150 cm 2 Culture dishes for transfection. Mix the four-plasmid system consisting of the lentiviral expression vector, helper plasmids gag / pol, Rev, and VSV-G with PEI transfection reagent, add to a defined volume of serum-free DMEM, mix thoroughly, and incubate for 15 minutes. Add this mixture to a 150 cm2 culture dish containing 293T cells, gently mix, and incubate in a 37°C, 5% CO2 incubator for 6 hours. After 6 hours, replace with fresh medium and continue incubation. Collect the lentiviral culture supernatant after 48 and 72 hours for infection. Transfer the harvested supernatant to a centrifuge tube and centrifuge at 4000 rpm for 10 minutes, with an ascending speed of 9 and a descending speed of 9, to remove cell debris. Filter and clarify the LVV supernatant through a 0.45 μm filter, and transfer the filtrate to a fresh centrifuge tube. Add the clarified lentiviral supernatant to an ultracentrifuge tube and balance on a scale. Place the balanced ultracentrifuge tubes into the hanging cups, which are then positioned in the corresponding positions of the rotor. Then, place the tubes in an ultracentrifuge and centrifuge at 4°C, 100,000 g, and 90 min, with both the ascent and descent speeds set to maximum. After ultracentrifugation, discard the supernatant, add 0.5 mL of culture medium to each tube, and resuspend at 2-8°C for 2 h. The harvested virus is then mixed with 1e6 NK92 cells in a 24-well plate and incubated in a CO2 incubator for 72 h.
[0257] Example 10. CAR-NK cell flow cytometry and sorting
[0258] Remove the cell suspension, wash three times with DPBS, centrifuge at 300g for 5 minutes, discard the supernatant, add the antibody cocktail (anti-FLAG-APC, 1:100 in DPBS), mix well, incubate at 4°C, stain for 30 minutes, wash three times with DPBS, and centrifuge at 300g for 5 minutes. Resuspend in DPBS and use for flow cytometry and flow sorting. During sorting, circle PE-positive cells and collect them in a 5ml flow cytometer. After sorting, centrifuge at 300g for 5 minutes, discard the supernatant, resuspend the cells in prewarmed culture medium, and incubate at 37°C, 5% CO2 in a cell culture incubator.
[0259] The sorted CAR-NK92 cells were stained with anti-FLAG-APC antibody, and the expression of CAR was detected by flow cytometry.
[0260] The results of flow cytometry are shown in Figure 10 , and the CAR positivity rate of the sorted NK92 C9 cells reached over 98%.
[0261] Example 11. CAR-NK killing experiment
[0262] Luciferase-labeled tumor target cells are used to test their killing ability. By transferring the luciferase gene into target cells, stably transfected cell lines expressing the Molm13, HL60, THP-1, and KG1 luciferase genes were obtained. During the experiment, the addition of a luciferin substrate causes the luciferase to react with the luciferin to produce fluorescence. The intensity of the fluorescence determines the luciferase activity, and the cell survival rate determines the killing effect on the effector cells.
[0263] The results are shown in Figure 11. NK92 C9 showed more obvious killing than NK92 on each target cell, suggesting a CAR-mediated killing effect.
[0264] Example 12. CAR-NK multiple rounds of killing experiments
[0265] One day before the experiment, THP1 cells with fluorescent target were resuspended and counted, and the cell density was adjusted to 8×10 4 / ml, 100ul per well of a 96-well plate. On the day of the experiment, take the corresponding number of NK92 and CAR-NK92 cells and add them to the wells. Place them in Cellcyte to start the experiment, and take pictures every 4 hours using bright field and fluorescence channels. Every two days is a round. After a round of killing, remove part of the supernatant, transfer it to a new plate with target cells, and place it in Cellcyte to start a new round of killing. The killing index is calculated by adjusting the zero-crossing time and the normal cell growth error, and then the reduction in the number of fluorescent cells is used to calculate the killing.
[0266] The results of multiple rounds of killing experiments are shown in Figure 12. NK92 C9 cells showed stronger killing ability than NK92 cells, suggesting that CAR-mediated killing is continuing to play a role.
[0267] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A nanobody that specifically binds to CLL1, characterized in that: The complementary determining region CDR region of the VHH chain in the Nanobody has the following CDR1, CDR2 and CDR3: (a) CDR1: the sequence of which is shown in SEQ ID No: 14, 11 or 20; (b) CDR2: the sequence of which is shown in SEQ ID No: 12, 15, 17, or 19; (c) CDR3: Its sequence is shown in SEQ ID No: 13, 16, 18, 21 or 22.
2. The Nanobody according to claim 1, characterized in that The complementarity determining region (CDR) region of the VHH chain in the Nanobody is selected from the following group: (Y1) CDR1 shown in SEQ ID NO: 14, CDR2 shown in SEQ ID NO: 19, and CDR3 shown in SEQ ID NO: 16; (Y2) CDR1 shown in SEQ ID NO: 14, CDR2 shown in SEQ ID NO: 12, and CDR3 shown in SEQ ID NO: 22; (Y3) CDR1 shown in SEQ ID NO: 14, CDR2 shown in SEQ ID NO: 15, and CDR3 shown in SEQ ID NO: 16; (Y4) CDR1 shown in SEQ ID NO: 14, CDR2 shown in SEQ ID NO: 17, and CDR3 shown in SEQ ID NO: 18; (Y5) CDR1 shown in SEQ ID NO: 14, CDR2 shown in SEQ ID NO: 19, and CDR3 shown in SEQ ID NO: 16; (Y6) CDR1 shown in SEQ ID NO: 11, CDR2 shown in SEQ ID NO: 12, and CDR3 shown in SEQ ID NO: 13; (Y7) CDR1 shown in SEQ ID NO:20, CDR2 shown in SEQ ID NO:12, and CDR3 shown in SEQ ID NO:
21.
3. The Nanobody according to claim 1, characterized in that The amino acid sequence of the nanobody that specifically binds to CLL1 is shown in any one of SEQ ID NOs: 1 to 10.
4. A multivalent antibody or an antibody against multiple epitopes that specifically binds to CLL1, characterized in that: The multivalent antibody or antibody against multiple epitopes comprises at least one antibody element against a CLL1 epitope, and the antibody element is the anti-CLL1 nanobody according to claim 1.
5. A recombinant protein, characterized in that The recombinant protein has: (i) the CLL1-specific binding Nanobody of claim 1, or the CLL1-specific binding multivalent antibody or antibody against multiple epitopes of claim 4; and (ii) optionally a tag sequence to facilitate expression and / or purification.
6. A chimeric antigen receptor (CAR) fusion protein, characterized in that The chimeric antigen receptor (CAR) fusion protein comprises from N-terminus to C-terminus: (i) an antigen binding domain that specifically binds to CLL1, wherein the antigen binding domain comprises the Nanobody of claim 1; (ii) transmembrane domain; (iii) at least one co-stimulatory domain; and (iv) Activation domain.
7. The CAR fusion protein according to claim 6, characterized in that The CAR has a structure shown in Formula Ia: L-VHH-FH-TM-C-CD3ζ (Ia) In the formula, Each "-" is independently a connecting peptide or a peptide bond; L is the signal peptide sequence; VHH is an antigen binding domain that specifically binds to CLL1; the amino acid sequence of the VHH is shown in any one of SEQ ID NOs: 1 to 10; F is none or Flag tag sequence (Flag tag); H is the hinge region; TM is the transmembrane domain; C is the co-stimulatory signaling domain; CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type, or mutant / modified form thereof).
8. The CAR fusion protein according to claim 6, characterized in that The CAR fusion protein has an amino acid sequence shown in any one of SEQ ID NOs: 32-41.
9. An antibody-drug conjugate, characterized in that: The antibody-drug conjugate contains: (a) the Nanobody according to claim 1, the multivalent antibody or the antibody against multiple epitopes according to claim 4, or the recombinant protein according to claim 5; as well as (b) a conjugated moiety conjugated to the antibody portion, wherein the conjugated moiety is selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.
10. A polynucleotide, characterized in that The polynucleotide encodes a protein selected from the group consisting of the nanobody of claim 1, the multivalent antibody or the antibody against multiple epitopes of claim 4, the recombinant protein of claim 5, or the CAR fusion protein of claim 6.
11. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 10.
12. A host cell, characterized in that The host cell contains the expression vector of claim 11, or the polynucleotide of claim 10 is integrated into its genome, or expresses the nanobody of claim 1, the multivalent antibody or the antibody against multiple epitopes of claim 4, the recombinant protein of claim 5, or the CAR fusion protein of claim 6.
13. A pharmaceutical composition, characterized in that The pharmaceutical composition contains: (i) the Nanobody of claim 1, or the multivalent antibody or antibody against multiple epitopes of claim 4, or the recombinant protein of claim 5, or an immune cell expressing the CAR fusion protein of claim 6; and (ii) a pharmaceutically acceptable carrier.
14. Use of the nanobody according to claim 1, or the multivalent antibody or antibody against multiple epitopes according to claim 4, or the recombinant protein according to claim 5, or an immune cell expressing the CAR fusion protein according to claim 6, characterized in that: Used for preparing drugs for preventing and / or treating tumors associated with CLL1.
15. A method for treating a disease, characterized in that: Comprising administering to a subject in need of treatment: The nanobody of claim 1, or the multivalent antibody or antibody against multiple epitopes of claim 4, or the recombinant protein of claim 5, or an immune cell expressing the CAR fusion protein of claim 6.
Citation Information
Patent Citations
Anti-CLL1 antibody and application thereof
CN113045658A
Targeting CLL1 chimeric antigen receptor and application thereof
CN113234169A
CLL1 and CD33 double-target chimeric antigen receptor and application thereof
CN113248621A
Anti-CLL1 single-domain antibody and application thereof
CN115772222A
